ArticleInternational journal of chronic obstructive pulmonary disease2026
Longitudinal Outcomes and Prognostic Risk of Normalized Airflow Obstruction in a Korean General Population Cohort.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Some individuals with airflow obstruction later show normalized spirometric values, but the clinical implications of this phenomenon in the general population are unclear. Methods: Using data from the Korean Genome and Epidemiology Study (KoGES), we examined the characteristics and prognosis of individuals with normalized airflow obstruction (NO), defined as FEV1/FVC <0.7 at baseline that normalized to ≥0.7 during follow-up. Results: Between 2000 and 2006, 4,807 participants were classified as NO (n=242), fixed obstruction (FO; persistent FEV1/FVC <0.7; n=277), or normal (FEV1/FVC ≥0.7 throughout; n=4,288). Over eight years of follow-up (2007-2014), the NO group contained more men, current smokers, and individuals with lower body mass index than the normal group and showed intermediate lung function between FO and normal groups. Annual FEV1 decline was similar across groups (-48.8 mL/year normal; -48.3 mL/year NO; -45.8 mL/year FO). However, by the end of the 12-year follow-up period, 37.2% of participants in the NO group developed airflow obstruction, with a 4.22-fold higher risk compared with the normal group (95% CI 3.26-5.46). Findings were consistent in a sensitivity analysis excluding individuals with excessive lung function variability. (HR 7.41, 95% CI 5.45-10.07). Discussion: These findings indicate that NO may represent a distinct and dynamic spirometric phenotype associated with increased risk of future airflow obstruction and highlight the need for early identification and preventive strategies in at-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.